|
1
|
Han S, Cui C, He H, Shen X, Chen Y, Wang
Y, Li D, Zhu Q and Yin H: FHL1 regulates myoblast differentiation
and autophagy through its interaction with LC3. J Cell Physiol.
235:4667–4678. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cao W, Liu J, Xia R, Lin L, Wang X, Xiao
M, Zhang C, Li J, Ji T and Chen W: X-linked FHL1 as a novel
therapeutic target for head and neck squamous cell carcinoma.
Oncotarget. 7:14537–14550. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu Y, Wang C, Cheng P, Zhang S, Zhou W,
Xu Y, Xu H and Ji G: FHL1 inhibits the progression of colorectal
cancer by regulating the Wnt/β-catenin signaling pathway. J Cancer.
12:5345–5354. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Keßler M, Kieltsch A, Kayvanpour E, Katus
HA, Schoser B, Schessl J, Just S and Rottbauer W: A zebrafish model
for FHL1-opathy reveals Loss-of-function effects of human FHL1
mutations. Neuromuscul Disord. 28:521–531. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li SZ, Hu YY, Zhao JL, Zang J, Fei Z, Han
H and Qin HY: Downregulation of FHL1 protein in glioma inhibits
tumor growth through PI3K/AKT signaling. Oncol Lett. 19:3781–3788.
2020.PubMed/NCBI
|
|
6
|
Ding J, Cong Y, Li F, Liu B, Wu D, Miao J
and Wang L: Muscle death participates in myofibrillar abnormalities
in FHL1 knockout mice. Biochem Biophys Res Commun. 523:105–111.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Weng J, Liao M, Zou S, Bao J, Zhou J, Qu
L, Feng R, Feng X, Zhao Z and Jing Z: Downregulation of FHL1
expression in thoracic aortic dissection: Implications in aortic
wall remodeling and pathogenesis of thoracic aortic dissection. Ann
Vasc Surg. 25:240–247. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee SMY, Tsui SKW, Chan KK, Garcia-Barcelo
M, Waye MM, Fung KP, Liew CC and Lee CY: Chromosomal mapping,
tissue distribution and cDNA sequence of Four-and-a-half LIM domain
protein 1 (FHL1). Gene. 216:163–170. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wilding BR, McGrath MJ, Bonne G and
Mitchell CA: FHL1 mutations that cause clinically distinct human
myopathies form protein aggregates and impair myoblast
differentiation. J Cell Sci. 127:2269–2281. 2014.PubMed/NCBI
|
|
10
|
Wei X and Zhang H: Four and a half LIM
domains protein 1 can be as a double-edged sword in cancer
progression. Cancer Biol Med. 17:270–281. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Selcen D, Bromberg MB, Chin SS and Engel
AG: Reducing bodies and myofibrillar myopathy features in FHL1
muscular dystrophy. Neurology. 77:1951–1959. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Isumi Y, Hirata T, Saitoh H, Miyakawa T,
Murakami K, Kudoh G, Doi H, Ishibashi K and Nakajima H: Transgenic
overexpression of USP15 in the heart induces cardiac remodeling in
mice. Biochem Biophys Res Commun. 405:216–221. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shathasivam T, Kislinger T and Gramolini
AO: Genes, proteins and complexes: The multifaceted nature of FHL
family proteins in diverse tissues. J Cell Mol Med. 14:2702–2720.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nishikawa M, Sato K, Nakano S, Yamakawa H,
Nagase T and Ueda H: Specific activation of PLEKHG2-induced serum
response element-dependent gene transcription by four-and-a-half
LIM domains (FHL) 1, but not FHL2 or FHL3. Small GTPases.
10:361–366. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zabalegui F, Castañeda SL, Amin G, Belli
C, Miriuka SG and Moro LN: Derivation of two human induced
pluripotent stem cell lines carrying a missense mutation in FHL1
(c.377G > A, p.C126Y) linked to familial muscular dystrophy.
Stem Cell Res. 75:1033072024. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
López Blázquez M, Fernández Ávila AI,
Álvarez García-Rovés R, Centeno Jiménez M, Gómez González C and
Espinosa Castro MÁ: Description of a novel variant in the FHL1 gene
associated with hypertrophic cardiomyopathy with early and
aggressive presentation. Rev Esp Cardiol (Engl Ed). 75:968–970.
2022.PubMed/NCBI
|
|
17
|
Albrecht I, Wick C, Hallgren Å, Tjärnlund
A, Nagaraju K, Andrade F, Thompson K, Coley W, Phadke A, Diaz-Gallo
LM, et al: Development of autoantibodies against muscle-specific
FHL1 in severe inflammatory myopathies. J Clin Invest.
125:4612–4624. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Martin DE, Soulard A and Hall MN: TOR
regulates ribosomal protein gene expression via PKA and the
forkhead transcription factor FHL1. Cell. 119:969–979. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ng WH, Liu X, Ling ZL, Santos CNO,
Magalhães LS, Kueh AJ, Herold MJ, Taylor A, Freitas JR, Koit S, et
al: FHL1 promotes chikungunya and o'nyong-nyong virus infection and
pathogenesis with implications for alphavirus vaccine design. Nat
Commun. 14:66052023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Meertens L, Hafirassou ML, Couderc T,
Bonnet-Madin L, Kril V, Kümmerer BM, Labeau A, Brugier A,
Simon-Loriere E, Burlaud-Gaillard J, et al: FHL1 is a major host
factor for chikungunya virus infection. Nature. 574:259–263. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Meertens L, Hafirassou ML, Couderc T,
Bonnet-Madin L, Kril V, Kümmerer BM, Labeau A, Brugier A,
Simon-Loriere E, Burlaud-Gaillard J, et al: FHL1 is a key player of
chikungunya virus tropism and pathogenesis. C R Biol. 343:79–89.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mota IA, Correia CdC, Fontana PN and
Carvalho AAS: Reducing body myopathy-A new pathogenic FHL1 variant
and literature review. Neuromuscul Disord. 31:847–853. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Binder MS, Brown E, Aversano T, Wagner KR,
Calkins H and Barth AS: Novel FHL1 mutation associated with
hypertrophic cardiomyopathy, sudden cardiac death, and myopathy.
JACC Case Rep. 2:372–377. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sakashita K, Mimori K, Tanaka F, Kamohara
Y, Inoue H, Sawada T, Hirakawa K and Mori M: Clinical significance
of loss of Fhl1 expression in human gastric cancer. Ann Surg Oncol.
15:2293–2300. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pereira CM, de Carvalho AC, da Silva FR,
Melendez ME, Lessa RC, Andrade VCC, Kowalski LP, Vettore AL and
Carvalho AL: In vitro and in silico validation of CA3 and FHL1
downregulation in oral cancer. BMC Cancer. 18:1932018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang Z, Zhang J, Yang B, Li R, Jin L, Wang
Z, Yu H, Liu C, Mao Y and You Q: Long intergenic noncoding RNA
00261 acts as a tumor suppressor in non-small cell lung cancer via
regulating miR-105/FHL1 axis. J Cancer. 10:6414–6421. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou F, Qian C, Chen T, Zang X and Huang
T: MiR-96-5p facilitates lung adenocarcinoma cell phenotypes by
inhibiting FHL1. Comput Math Methods Med. 2022:78912222022.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang F, Su Q and Li C: Identidication of
novel biomarkers in Non-small cell lung cancer using machine
learning. Sci Rep. 12:166932022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen H, Lai X, Zhu Y, Huang H, Zeng L and
Zhang L: Quantitative proteomics identified circulating biomarkers
in lung adenocarcinoma diagnosis. Clin Proteomics. 19:442022.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Song J, Liang K, Wei T, Li L, Huang Z,
Chen G, Mao N and Yang J: Expression and predictive significance of
FHL1 and SLIT3 in surgically resected lung adenocarcinoma. Comb
Chem High Throughput Screen. 26:2226–2237. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang F, Lian M, Ma H, Feng L, Shen X, Chen
J and Fang J: Identification of key genes associated with papillary
thyroid microcarcinoma characteristics by integrating transcriptome
sequencing and weighted gene co-expression network analysis. Gene.
811:1460862022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li Y, Zeng Qa, Qiu J, Pang T, Ye F, Huang
L and Zhang X: MiR-183-5p promotes proliferation, metastasis and
angiogenesis in breast cancer cells through negatively regulating
four and a Half LIM protein 1. J Breast Cancer. 23:355–372. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang Y, Fu J, Jiang M, Zhang X, Cheng L,
Xu X, Fan Z, Zhang J, Ye Q and Song H: MiR-410 is overexpressed in
liver and colorectal tumors and enhances tumor cell growth by
silencing FHL1 via a Direct/Indirect mechanism. PLoS One.
9:e1087082014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ji C, Liu H, Xiang M, Liu J, Yue F, Wang W
and Chu X: Deregulation of decorin and FHL1 are associated with
esophageal squamous cell carcinoma progression and poor prognosis.
Int J Clin Exp Med. 8:20965–20970. 2015.PubMed/NCBI
|
|
35
|
Eshibona N, Giwa A, Rossouw SC, Gamieldien
J, Christoffels A and Bendou H: Upregulation of FHL1, SPNS3, and
MPZL2 predicts poor prognosis in pediatric acute myeloid leukemia
patients with FLT3-ITD mutation. Leuk Lymphoma. 63:1897–1906. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang J, Hu X, Liu S, He Y, Lyu L and
Jiang L: Clinical value screening, prognostic significance, and key
gene identification of TrkB in laryngeal carcinoma. Dis Markers.
2022:13540052022.PubMed/NCBI
|
|
37
|
Das K, Chan XB, Epstein D, Te Teh B, Kim
KM, Kim ST, Park SH, Kang WK, Rozen S, Lee J and Tan P: NanoString
expression profiling identifies candidate biomarkers of RAD001
response in metastatic gastric cancer. ESMO Open. 1:e0000092016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu1 P, Ma Q, Chen H, Zhang L and Zhang X:
Identification of RHOBTB2 aberration as an independent prognostic
indicator in acute myeloid leukemia. Aging (Albany NY).
13:15269–15284. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu Y, Li H, Zhao Y, Li D, Zhang Q, Fu J
and Fan S: Targeting FHL1 impairs cell proliferation and
differentiation of acute myeloid leukemia cells. Biochem Cell Biol.
100:301–308. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Luo Q, Pan Y, Fu Q, Zhang X, Zhou S, Yu P,
Tian H, Liu P, Chen S, Zhang H and Qin T:
Immortalization-upregulated protein promotes pancreatic cancer
progression by regulating NPM1/FHL1-mediated cell-cycle-checkpoint
protein activity. Cell Biol Toxicol. 39:2069–2087. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lin J, Ding L, Jin R, Zhang H, Cheng L,
Qin X, Chai J and Ye Q: Four and a half LIM domains 1 (FHL1) and
receptor interacting protein of 140 kDa (RIP140) interact and
cooperate in estrogen signaling. Int J Biochem Cell Biol.
41:1613–1618. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li X, Jia Z, Shen Y, Ichikawa H, Jarvik J,
Nagele RG and Goldberg GS: Coordinate suppression of Sdpr and Fhl1
expression in tumors of the breast, kidney, and prostate. Cancer
Sci. 99:1326–1333. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Koike K, Kasamatsu A, Iyoda M, Saito Y,
Kouzu Y, Koike H, Sakamoto Y, Ogawara K, Tanzawa H and Uzawa K:
High prevalence of epigenetic inactivation of the human four and a
half LIM domains 1 gene in human oral cancer. Int J Oncol.
42:141–150. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Asada K, Ando T, Niwa T, Nanjo S, Watanabe
N, Okochi-Takada E, Yoshida T, Miyamoto K, Enomoto S, Ichinose M,
et al: FHL1 on chromosome X is a single-hit gastrointestinal
tumor-suppressor gene and contributes to the formation of an
epigenetic field defect. Oncogene. 32:2140–2149. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chen X, Yu Y, Su Y, Shi L, Xie S, Hong Y,
Liu X and Yin F: Low FHL1 expression indicates a good prognosis and
drug sensitivity in ovarian cancer. Funct Integr Genomics.
24:252024. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sun L, Chen L, Zhu H, Li Y, Chen CC and Li
M: FHL1 promotes glioblastoma aggressiveness through regulating
EGFR expression. FEBS Lett. 595:85–98. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang X, Wei X, Yuan Y, Sun Q, Zhan J,
Zhang J, Tang Y, Li F, Ding L, Ye Q and Zhang H: Src-mediated
phosphorylation converts FHL1 from tumor suppressor to tumor
promoter. J Cell Biol. 217:1335–1351. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Shi MK, Xuan YL and He XF: FHL1
overexpression as a inhibitor of lung cancer cell invasion via
increasing RhoGDIß mRNA expression. Cell J. 24:239–244.
2022.PubMed/NCBI
|
|
49
|
Matsumoto M, Kawakami K, Enokida H, Toki
K, Matsuda R, Chiyomaru T, Nishiyama K, Kawahara K, Seki N and
Nakagawa M: CpG hypermethylation of human four-and-a-half LIM
domains 1 contributes to migration and invasion activity of human
bladder cancer. Int J Mol Med. 26:241–247. 2010.PubMed/NCBI
|
|
50
|
Yi S, Luo M, Peng Y, Chen Y and Yu D:
Anti-oncogenic mechanism of KLF17 in colon cancer by repressing
cell migration and invasion via FHL1 upregulation. Chi J Physiol.
66:534–545. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chen Y, Pei M, Li J, Wang Z, Liu S, Xiang
L, Zhang J, Hong L, Lin J, Dai W, et al: Disruption of the
CCDC43-FHL1 interaction triggers apoptosis in gastric cancer cells.
Exp Cell Res. 415:1131072022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhou Z, Lu J, Dou J, Lv Z, Qin XI and Lin
J: FHL1 and Smad4 synergistically inhibit vascular endothelial
growth factor expression. Mol Med Rep. 7:649–653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Niu C, Liang C, Guo J, Cheng L, Zhang H,
Qin X, Zhang Q, Ding L, Yuan B, Xu X, et al: Downregulation and
growth inhibitory role of FHL1 in lung cancer. Int J Cancer.
130:2549–2556. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ding L, Niu C, Zheng Y, Xiong Z, Liu Y,
Lin J, Sun H, Huang K, Yang W, Li X and Ye Q: FHL1 interacts with
oestrogen receptors and regulates breast cancer cell growth. J Cell
Mol Med. 15:72–85. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhang Q, Li J, Chen Z, Jiang K, Yang K,
Huang F, Huang A, Zhang X, Zhang J and Wang H: VE-822 upregulates
the deubiquitinase OTUD1 to stabilize FHL1 to inhibit the
progression of lung adenocarcinoma. Cell Oncol. 46:1001–1014. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lin J, Qin X, Zhu Z, Mu J, Zhu L, Wu K,
Jiao H, Xu X and Ye Q: FHL family members suppress vascular
endothelial growth factor expression through blockade of
dimerization of HIF1α and HIF1β. IUBMB Life. 64:921–930. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zhang J, Li H, Guo M, Zhang J, Zhang G,
Sun N, Feng Y, Cui W and Xu F: FHL1 as a novel prognostic biomarker
and correlation with immune infiltration levels in lung
adenocarcinoma. Immunotherapy. 15:235–252. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ding L, Wang Z, Yan J, Yang X, Liu A, Qiu
W, Zhu J, Han J, Zhang H, Lin J, et al: Human four-and-a-half LIM
family members suppress tumor cell growth through a TGF-β-like
signaling pathway. J Clin Invest. 119:349–361. 2009.PubMed/NCBI
|
|
59
|
Chen J, Zeng C, Jin J, Zhang P, Zhang Y,
Zhang H, Li Y and Guan H: Overexpression of FHL1 suppresses
papillary thyroid cancer proliferation and progression via
inhibiting Wnt/β-catenin pathway. Endocrine. 85:238–249. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Xu X, Fan Z, Liang C, Li L, Wang L, Liang
Y, Wu J, Chang S, Yan Z, Lv Z, et al: A signature motif in LIM
proteins mediates binding to checkpoint proteins and increases
tumour radiosensitivity. Nat Commun. 8:140592017. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Fu Y, Xu M, Cui Z, Yang Z, Zhang Z, Yin X,
Huang X, Zhou M, Wang X and Chen C: Genome-wide identification of
FHL1 as a powerful prognostic candidate and potential therapeutic
target in acute myeloid leukaemia. EBioMedicine. 52:1026642020.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Chen X, Yan Y, Liu Y, Yi Q and Xu Z:
Tabersonine enhances olaparib sensitivity through FHL1-Mediated
Epithelial-mesenchymal transition in an ovarian tumor. J Nat Prod.
87:837–848. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Liu M, Meng J, Chen X, Wang F and Han Z:
Long non-coding RNA Small Nucleolar RNA Host Gene 4 ameliorates
cigarette Smoke-induced proliferation, apoptosis, inflammation, and
airway remodeling in alveolar epithelial cells through the
modulation of the mitogen-activated protein kinase signaling
pathway via the microRNA-409-3p/Four and a Half LIM Domains 1 axis.
Eur J Med Res. 29:3092024. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Ding J, Cong YF and Liu B: Aberrant
protein turn-over associated with myofibrillar disorganization in
FHL1 knockout mice. Front Genet. 9:2732018. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Wong CH, Fung YW, Ng EK, Lee SM, Waye MM
and Tsui SK: LIM domain protein FHL1B interacts with PP2A catalytic
β subunit-A novel cell cycle regulatory pathway. FEBS Lett.
584:4511–4516. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Wu J, Zhao K, Du Z, Chen Y, Zhang F, Jiang
W, Zheng J, Wu X, Shen C and Xiao X: Systemic effect of FHL1 on
neuromuscular junction and myotube formation via insulin-like
growth factor and myostatin signaling pathways. Biochem Biophys Res
Commun. 537:125–131. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Schreckenbach T, Henn W, Kress W, Roos A,
Maschke M, Feiden W, Dillmann U, Schulz JB, Weis J and Claeys KG:
Novel FHL1 mutation in a family with reducing body myopathy. Muscle
Nerve. 47:127–134. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Peters S: Electrocardiographic analysis in
unclassifiable arrhythmic cardiomyopathy associated with
Emery-Dreifuss caused by a mutation in FHL1. Int J Cardiol.
214:1362016. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Luo YB, Peng Y, Lu Y, Li Q, Duan H, Bi F
and Yang H: Expanding the Clinico-genetic spectrum of myofibrillar
myopathy: Experience from a Chinese neuromuscular center. Front
Neurol. 11:10142020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Hu Z, Zhu Y, Liu X, Zhang W, Liu J, Wu S,
Xiao J, Yuan Y and Wang Z: FHL1-related clinical, muscle MRI and
genetic features in six Chinese patients with reducing body
myopathy. J Hum Genet. 64:919–926. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Sepp R, Hategan L, Csányi B, Borbás J,
Tringer A, Pálinkás ED, Nagy V, Takács H, Latinovics D, Nyolczas N,
et al: The genetic architecture of hypertrophic cardiomyopathy in
hungary: Analysis of 242 patients with a panel of 98 genes.
Diagnostics (Basel). 12:11322022. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Lin Y, Ban R, Qiao L, Chen J, Liu M, Liu J
and Shi Q: Identification of novel FHL1 mutations associated with
X-linked scapuloperoneal myopathy in unrelated Chinese patients. J
Hum Genet. 68:477–484. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Liu E, Jelinek J, Pastore YD, Guan Y,
Prchal JF and Prchal JT: Discrimination of polycythemias and
thrombocytoses by novel, simple, accurate clonality assays and
comparison with PRV-1 expression and BFU-E response to
erythropoietin. Blood. 101:3294–3301. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Zhang F, Feng F, Yang P, Li Z, You J, Xie
W, Gao X and Yang J: Four-and-a-half-LIM protein 1 down-regulates
estrogen receptor α activity through repression of AKT
phosphorylation in human breast cancer cell. Int J Biochem Cell
Biol. 44:320–326. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Zeng Y, Zeng D, Qi X, Wang H, Wang X, Dai
X and Qu L: FHL1: A novel diagnostic marker for papillary thyroid
carcinoma. Pathol Int. 74:520–529. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Balraj A, Muthamilselvan S, Raja R and
Palaniappan A: PRADclass: Hybrid Gleason grade-informed
computational strategy identifies consensus biomarker features
predictive of aggressive prostate adenocarcinoma. Technol Cancer
Res Treat. 23:153303382312223892024. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Cai Y, Xia L, Zhu H, Cheng H, Tian Y, Sun
L, Wang J, Lu N, Wang J and Chen Y: MiR-3682-3p promotes esophageal
cancer progression by targeting FHL1 and activating the
Wnt/β-catenin signaling pathway. Cell Signal. 119:1111552024.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Zhao JL, Liang SQ, Fu W, Zhu BK, Li SZ,
Han H and Qin HY: The LIM domain protein FHL1C interacts with tight
junction protein ZO-1 contributing to the epithelial-mesenchymal
transition (EMT) of a breast adenocarcinoma cell line. Gene.
542:182–189. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Dai J, Yu X, Han Y, Chai L, Liao Y, Zhong
P, Xie R, Sun X, Huang Q and Wang J: TMT-labeling proteomics of
papillary thyroid carcinoma reveal invasive biomarkers. J Cancer.
11:6122–6132. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Fu W, Wang K, Zhao JL, Yu HC, Li SZ, Lin
Y, Liang L, Huang SY, Liang YM, Han H and Qin HY: FHL1C induces
apoptosis in notch1-dependent T-ALL cells through an interaction
with RBP-J. BMC Cancer. 14:4632014. View Article : Google Scholar : PubMed/NCBI
|
